UniProtKB/Swiss-Prot P02489 : Variant p.Arg21Trp
Alpha-crystallin A chain
Gene: CRYAA
Feedback ?
Variant information
Variant position:
21
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:
LP/P [Disclaimer : Variants classification is intended for research purposes only, not for clinical and diagnostic use . The label disease variant is assigned according to literature reports on probable disease-association that can be based on theoretical reasons. This label must not be considered as a definitive proof for the pathogenic role of a variant. ]
The variants are classified into three categories: LP/P, LB/B and US.LP/P: likely pathogenic or pathogenic. LB/B: likely benign or benign. US: uncertain significance
Residue change:
From Arginine (R) to Tryptophan (W) at position 21 (R21W, p.Arg21Trp).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:
Change from large size and basic (R) to large size and aromatic (W)
The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:
-3
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another: Lowest score: -4 (low probability of substitution).Highest score: 11 (high probability of substitution). More information can be found on the following page
Variant description:
In CTRCT9.
Any additional useful information about the variant.
Other resources:
Links to websites of interest for the variant.
Sequence information
Variant position:
21
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:
173
The length of the canonical sequence.
Location on the sequence:
MDVTIQHPWFKRTLGPFYPS
R LFDQFFGEGLFEYDLLPFLS
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:
The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human MDVTIQHPWFKRTLGPFYPSR LFDQFFGEGLFEYDLLPFLS
MDIAIQHPWFKRALGPFYPSR LFDQFFGEGLFEYDLLPFLS
Rhesus macaque MDVTIQHPWFKRTLGPFYPSR LFDQFFGEGLFEYDLLPFLS
Mouse MDVTIQHPWFKRALGPFYPSR LFDQFFGEGLFEYDLLPFLS
Rat MDVTIQHPWFKRALGPFYPSR LFDQFFGEGLFEYDLLPFLS
Pig MDIAIQHPWFKRALGPFYPSR LFDQFFGEGLFEYDLLPFLS
Bovine MDIAIQHPWFKRTLGPFYPSR LFDQFFGEGLFEYDLLPFLS
Rabbit MDVTIQHPWFKRTLGPFYPSR LFDQFFGEGLFEYDLLPFLS
Sheep MDIAIQHPWFKRTLGPFYPSR LFDQFFGEGLFEYDLLPFLS
Cat MDIAIQHPWFKRALGPFYPSR LFDQFFGEGLFEYDLLPFLS
Horse MDIAIQHPWFKRALGPFYPSR LFDQFFGEGLFEYDLLPFLS
Chicken MDITIQHPWFKRALGPLIPSR LFDQFFGEGLLEYDLLPLFS
Sequence annotation in neighborhood:
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
1 – 173
Alpha-crystallin A chain
Chain
1 – 172
Alpha-crystallin A(1-172)
Chain
1 – 168
Alpha-crystallin A(1-168)
Chain
1 – 162
Alpha-crystallin A(1-162)
Region
1 – 63
Required for complex formation with BFSP1 and BFSP2; during homooligomerization, mediates the association of 2 dimers to form a tetramer
Site
1 – 1
Susceptible to oxidation
Site
18 – 18
Susceptible to oxidation
Site
34 – 34
Susceptible to oxidation
Modified residue
1 – 1
N-acetylmethionine
Modified residue
6 – 6
Deamidated glutamine; partial
Literature citations
Genetic heterogeneity in microcornea-cataract: five novel mutations in CRYAA, CRYGD, and GJA8.
Hansen L.; Yao W.; Eiberg H.; Kjaer K.W.; Baggesen K.; Hejtmancik J.F.; Rosenberg T.;
Invest. Ophthalmol. Vis. Sci. 48:3937-3944(2007)
Cited for: VARIANTS CTRCT9 CYS-12 AND TRP-21;
Crystallin gene mutations in Indian families with inherited pediatric cataract.
Devi R.R.; Yao W.; Vijayalakshmi P.; Sergeev Y.V.; Sundaresan P.; Hejtmancik J.F.;
Mol. Vis. 14:1157-1170(2008)
Cited for: VARIANTS CTRCT9 CYS-12; TRP-21 AND CYS-54;
Comprehensive mutational screening in a cohort of Danish families with hereditary congenital cataract.
Hansen L.; Mikkelsen A.; Nuernberg P.; Nuernberg G.; Anjum I.; Eiberg H.; Rosenberg T.;
Invest. Ophthalmol. Vis. Sci. 50:3291-3303(2009)
Cited for: VARIANTS CTRCT9 TRP-21 AND CYS-49;
Pathogenic mutations in two families with congenital cataract identified with whole-exome sequencing.
Kondo Y.; Saitsu H.; Miyamoto T.; Lee B.J.; Nishiyama K.; Nakashima M.; Tsurusaki Y.; Doi H.; Miyake N.; Kim J.H.; Yu Y.S.; Matsumoto N.;
Mol. Vis. 19:384-389(2013)
Cited for: VARIANT CTRCT9 TRP-21;
Mutations in crystallin genes result in congenital cataract associated with other ocular abnormalities.
Sun Z.; Zhou Q.; Li H.; Yang L.; Wu S.; Sui R.;
Mol. Vis. 23:977-986(2017)
Cited for: VARIANT CTRCT9 TRP-21;
Clinical and genetic characteristics of Chinese patients with familial or sporadic pediatric cataract.
Li J.; Leng Y.; Han S.; Yan L.; Lu C.; Luo Y.; Zhang X.; Cao L.;
Orphanet J. Rare Dis. 13:94-94(2018)
Cited for: VARIANT CTRCT9 TRP-21;
Mutation screening of crystallin genes in Chinese families with congenital cataracts.
Zhuang J.; Cao Z.; Zhu Y.; Liu L.; Tong Y.; Chen X.; Wang Y.; Lu C.; Ma X.; Yang J.;
Mol. Vis. 25:427-437(2019)
Cited for: VARIANTS CTRCT9 LEU-12; TRP-21 AND CYS-116;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.